miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer.


Journal

Oncology reports
ISSN: 1791-2431
Titre abrégé: Oncol Rep
Pays: Greece
ID NLM: 9422756

Informations de publication

Date de publication:
08 2020
Historique:
received: 21 11 2019
accepted: 29 04 2020
pubmed: 30 5 2020
medline: 9 3 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

Recent studies have revealed the oncogenic role of notch reporter 3 (NOTCH3) in ovarian cancer (OC). However, the possible regulators and mechanisms underlying notch receptor 3 (NOTCH3)‑mediated behaviors in OC remain to be completely investigated. In the present study, we aimed to identify regulators of NOTCH3 and their interactions underlying the pathogenesis of OC. Bioinformatics analysis and luciferase reporter assay were used to identify potential regulatory miRNAs and lncRNAs of NOTCH3 in OC. Several in vivo and in vitro assays were performed to evaluate their effects on the proliferative ability mediated by NOTCH3. We identified microRNA‑1299 (miR‑1299) as a novel negative regulator of NOTCH3. miR‑1299 was downregulated in OC and was found to be considerably correlated with tumor differentiation. Upregulation of miR‑1299 inhibited cell proliferation, colony formation, and 5‑ethynyl‑2'‑deoxyuridine (EdU) incorporation, as well as induced cell cycle arrest in the G0G1 phase in OC cells. Overexpression of miR‑1299 in xenograft mouse models suppressed tumor growth in vivo. The lncRNA taurine upregulated gene 1 (TUG1), acting as a sponge of miR‑1299, was found to upregulate NOTCH3 expression and promote cell proliferation in OC through the competing endogenous RNA mechanism. In addition, TUG1 was found to be a potential downstream target of NOTCH3, forming a miR‑1299/NOTCH3/TUG1 feedback loop in the development of OC. Collectively, our findings improve the understanding of NOTCH3‑mediated regulation in OC pathogenesis and facilitate the development of miRNA‑ and lncRNA‑directed diagnostics and therapeutics against this disease.

Identifiants

pubmed: 32468036
doi: 10.3892/or.2020.7623
pmc: PMC7336509
doi:

Substances chimiques

MIRN1299 microRNA, human 0
MicroRNAs 0
NOTCH3 protein, human 0
RNA, Long Noncoding 0
Receptor, Notch3 0
TUG1 long noncoding RNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

438-448

Commentaires et corrections

Type : ErratumIn

Références

Mol Cancer. 2019 Jul 4;18(1):115
pubmed: 31272462
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Cell Death Dis. 2017 Oct 12;8(10):e3104
pubmed: 29022920
J Ovarian Res. 2014 Nov 04;7:95
pubmed: 25366565
Cell Physiol Biochem. 2018;49(6):2511-2520
pubmed: 30261503
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Trends Biochem Sci. 2016 Sep;41(9):761-772
pubmed: 27499234
Cancer Res. 2006 Jun 15;66(12):6312-8
pubmed: 16778208
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700
Nat Commun. 2016 Dec 06;7:13616
pubmed: 27922002
Cancer Res. 2014 Jun 15;74(12):3282-93
pubmed: 24743243
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Nucleic Acids Res. 2013 Jan;41(Database issue):D983-6
pubmed: 23175614
Mol Cancer Res. 2018 Nov;16(11):1665-1675
pubmed: 30072582
J Cell Biochem. 2020 Feb;121(2):1039-1049
pubmed: 31490018
Nat Commun. 2019 Feb 8;10(1):663
pubmed: 30737378
Clin Exp Immunol. 2020 Apr;200(1):45-52
pubmed: 31821542
Cell Physiol Biochem. 2017;42(6):2145-2158
pubmed: 28813705
Cancer Treat Rev. 2016 Jan;42:41-6
pubmed: 26559739
Cancer Res. 2012 May 1;72(9):2294-303
pubmed: 22396495
Nat Commun. 2016 Mar 15;7:10982
pubmed: 26975529
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancer Sci. 2010 Sep;101(9):1977-83
pubmed: 20624166
Cancer Lett. 2020 Jan 28;469:54-67
pubmed: 31629932
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cell Physiol Biochem. 2018;48(5):1928-1941
pubmed: 30092578
Nucleic Acids Res. 2018 Jan 4;46(D1):D1284
pubmed: 29161433
J Cell Biochem. 2019 Aug;120(8):12684-12693
pubmed: 30993801
Nature. 2012 Sep 6;489(7414):101-8
pubmed: 22955620
Am J Pathol. 2010 Sep;177(3):1087-94
pubmed: 20671266
Mol Ther Nucleic Acids. 2019 Jun 7;16:257-271
pubmed: 30925453
Mol Ther Nucleic Acids. 2018 Sep 7;12:229-241
pubmed: 30195762
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Semin Cancer Biol. 2017 Jun;44:67-71
pubmed: 28450177
J Hepatol. 2017 Sep;67(3):603-618
pubmed: 28438689
Autophagy. 2019 Jun;15(6):1100-1111
pubmed: 30654687
Int J Cancer. 2014 Sep 15;135(6):1286-96
pubmed: 24510775
Aging (Albany NY). 2019 Sep 18;11(18):7553-7569
pubmed: 31532756
Cancer Sci. 2017 May;108(5):859-867
pubmed: 28205334
Cancer Res. 2019 Sep 15;79(18):4612-4626
pubmed: 31331909
Mediators Inflamm. 2016;2016:5953498
pubmed: 27445438
Biomed Pharmacother. 2016 Oct;83:792-797
pubmed: 27490780
BMC Cancer. 2014 Feb 11;14:80
pubmed: 24512620
Nucleic Acids Res. 2013 Jan;41(Database issue):D239-45
pubmed: 23193281
Exp Mol Pathol. 2016 Oct;101(2):267-273
pubmed: 27693324
PLoS One. 2018 Oct 18;13(10):e0206239
pubmed: 30335862
Gynecol Oncol. 2013 Jul;130(1):200-6
pubmed: 23542683
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Trends Cell Biol. 2018 Apr;28(4):287-301
pubmed: 29274663
Trends Cancer. 2019 Sep;5(9):524-528
pubmed: 31474356
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Oncol Res. 2017 May 24;25(5):789-798
pubmed: 27983921
J Exp Clin Cancer Res. 2018 May 18;37(1):106
pubmed: 29776371
Front Genet. 2012 Jan 09;2:107
pubmed: 22303401
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Br J Cancer. 2011 Sep 27;105(7):890-6
pubmed: 21878937
Oncogene. 2020 Jan;39(4):862-876
pubmed: 31570789
Nat Commun. 2019 Feb 18;10(1):809
pubmed: 30778058
Histopathology. 2012 Apr;60(5):826-37
pubmed: 22348356
Anticancer Res. 2013 Mar;33(3):801-8
pubmed: 23482747
Int J Oncol. 2016 Jan;48(1):181-90
pubmed: 26575700
Cell Cycle. 2013 Jan 15;12(2):191-2
pubmed: 23287472
Medicine (Baltimore). 2018 May;97(19):e0575
pubmed: 29742691
Curr Biol. 2005 Mar 29;15(6):501-12
pubmed: 15797018
Mol Cancer. 2017 Jul 11;16(1):118
pubmed: 28697764

Auteurs

Yuqing Pei (Y)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Kexin Li (K)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Xiaoying Lou (X)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Yue Wu (Y)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Xin Dong (X)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Wenpeng Wang (W)

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.

Ning Li (N)

Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Donghong Zhang (D)

Center for Molecular and Translational Medicine, Research Science Center, Georgia State University, Atlanta, GA 30303, USA.

Wei Cui (W)

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH